Kuo B, Castell D O
Department of Medicine, Graduate Hospital, Philadelphia, Pennsylvania, USA.
Am J Gastroenterol. 1996 Aug;91(8):1532-8.
Little is known about the best regimen of omeprazole 40 mg/day for suppressing gastric acid and distal esophageal acid exposure. In addition, the relationship between the level of serum gastrin and gastric pH and this therapy is still uncertain.
Nineteen healthy male volunteers (mean age 25 yr) had a baseline fasting serum gastrin and 24-h ambulatory combined distal esophageal and gastric pH monitoring. Subjects underwent a 7-day course of each of three specific regimens of omeprazole 40 mg (20 mg b.i.d., 40 mg qAM, 40 mg qPM) with repeat pH and gastrin on day 6. Meals and activity patterns were constant for each subject during the test series. Medications were taken before meals.
All dosing regimens caused significant (p < 0.01) acid reduction compared with baseline in both the stomach and the distal esophagus. There was no significant difference in the amount of acid exposure (time pH < 4) among the three dosing regimens in the esophagus and between qAM and qAM dosing in the stomach. However, b.i.d. dosing gave better (p < 0.05) gastric acid suppression compared with single daily dosing in 15 of 19 subjects. When the baseline was compared with all regimens of omeprazole 40 mg, there was a significant difference with both the serum gastrin (p < 0.01) and the percentage time gastric pH was < 4 (p < 0.01). The correlation between change in serum gastrin and change in percentage time gastric pH was < 4 was poor (r = 0.26).
Divided dosing of omeprazole 20 mg b.i.d. provides superior gastric acid suppression to either once a day regimen of omeprazole 40 mg in most individuals. Serum gastrin levels do not correspond well to gastric pH, necessitating the use of gastric pH monitoring to accurately determine the response to gastric acid suppression.
对于每日40毫克奥美拉唑抑制胃酸及远端食管酸暴露的最佳治疗方案,人们了解甚少。此外,血清胃泌素水平与胃pH值之间的关系以及这种治疗方法仍不明确。
19名健康男性志愿者(平均年龄25岁)进行了基线空腹血清胃泌素检测以及24小时动态食管远端和胃pH联合监测。受试者接受三种特定的40毫克奥美拉唑治疗方案(20毫克每日两次、40毫克每日清晨一次、40毫克每日傍晚一次),疗程均为7天,并在第6天重复进行pH和胃泌素检测。在测试系列中,每个受试者的饮食和活动模式保持不变。药物在饭前服用。
与基线相比,所有给药方案在胃和食管远端均导致显著(p < 0.01)的酸减少。三种给药方案在食管中的酸暴露量(pH < 4的时间)以及胃中每日清晨一次给药和每日傍晚一次给药之间均无显著差异。然而,在19名受试者中的15名中,每日两次给药与单次每日给药相比,胃酸抑制效果更好(p < 0.05)。当将基线与所有40毫克奥美拉唑方案进行比较时,血清胃泌素(p < 0.01)以及胃pH < 4的时间百分比(p < 0.01)均存在显著差异。血清胃泌素变化与胃pH < 4的时间百分比变化之间的相关性较差(r = 0.26)。
在大多数个体中,每日两次服用20毫克奥美拉唑的分次给药方案比每日一次服用40毫克奥美拉唑的方案能提供更好的胃酸抑制效果。血清胃泌素水平与胃pH值的对应关系不佳,因此需要使用胃pH监测来准确确定对胃酸抑制的反应。